Abstract
The relationship between glaucoma medications and ocular surface disease (OSD) has been investigated for a long time by ophthalmologists. It has been well known that all preservatives used in topical medications have the potential to cause corneal and conjunctival changes, including dry eye. It is important to also consider the toxicity of the active ingredients. Objective tests for evaluating OSD are the Schirmer Test, Tear Break Up Time (TBUT), Fluorescein Clearance Test (FCT), impression cytology, confocal microscopy the most common subjective test is Ocular Surface Disease Index (OSDI). Adverse effects associated with topical medication may have a negative effect on patient adherence to medical treatment, the patients life quality and the doctorpatient relationship. A favourable adherence to treatment will lead to more effective intraocular pressure (IOP) lowering and resultant decrease of glaucomatous vision loss.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
